Table 3.
Serum ghrelin: continuous1 | Serum ghrelin: quartiles | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Group | Q1 | Q2 | Q3 | Q4 | |||||||
OR | 95% CI | Pvalue | OR | 95% CI | OR | 95% CI | OR | 95% CI | Ptrend | ||
Colorectal cancer (n=523) | |||||||||||
Case number | n = 185 | n =110 | n =103 | n =125 | |||||||
Crude | 1.05 | 0.99, 1.12 | 0.11 | 1.65 | 1.15, 2.34 | 0.95 | 0.66, 1.35 | 0.86 | 0.61, 1.21 | REF | 0.01 |
Multivariable2 | 1.04 | 0.97, 1.11 | 0.29 | 1.57 | 1.05, 2.34 | 0.92 | 0.62, 1.34 | 0.84 | 0.58, 1.20 | REF | 0.03 |
Colon cancer (n=284) | |||||||||||
Case number | n = 103 | n = 58 | n =54 | n = 69 | |||||||
Crude | 1.04 | 0.95, 1.14 | 0.40 | 1.56 | 0.96, 2.54 | 0.80 | 0.50, 1.28 | 0.81 | 0.50, 1.30 | REF | 0.13 |
Multivariable2 | 1.00 | 0.91, 1.11 | 0.93 | 1.37 | 0.78, 2.40 | 0.66 | 0.39, 1.14 | 0.73 | 0.43, 1.22 | REF | 0.38 |
Rectal cancer (n=239) | |||||||||||
Case number | n = 82 | n = 52 | n = 49 | n = 56 | |||||||
Crude | 1.08 | 0.97, 1.18 | 0.15 | 1.82 | 1.05, 3.15 | 1.18 | 0.68, 2.05 | 0.94 | 0.56, 1.57 | REF | 0.02 |
Multivariable2 | 1.08 | 0.97, 1.20 | 0.15 | 2.14 | 1.13, 4.03 | 1.27 | 0.70, 2.30 | 0.98 | 0.57, 1.70 | REF | 0.01 |
Continuous ORs are scaled to 176 pg/mL, which is one half of the inter-quartile range in the controls (75th percentile – 25th percentile ÷ 2) and interpreted as the change per unit decrease in serum ghrelin.
Adjusted ORs and 95% CIs were calculated using models which included: education (post-primary school), total years of smoking, total cigarettes/day, BMI (kg/m2), diabetes (either self-reported history of diabetes or blood glucose ≥ 126 mg/dL), daily analgesic use for >1 month (yes/no), alcohol (g/day), red meat consumption (g/day), processed meat consumption (g/day), fruit intake (g/day), vegetable intake (g/day), total dietary fiber (g/day), and ATBC treatment group assignment